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ABSTRACT
PHOTODYNAMIC THERAPY FOR CUTANEOUS SQUAMOUS CELL
CARCINOMA IN-SITU & MUTATION BURDEN ANALYSIS. Yuemei (Amy) Zhang,
Mei Zhong, Haifan Lin, and Sean Christensen. Department of Dermatology, Yale
University School of Medicine, New Haven, CT.
SCC in-situ (SCCIS), or Bowen’s disease, is a precursor to invasive squamous
cell carcinoma (SCC) of the skin. Compared to other available treatment modalities,
photodynamic therapy (PDT) may offer comparable efficacy with decreased morbidity
and better cosmetic and functional outcomes. This retrospective study analyzes the
effectiveness and outcomes of photodynamic therapy with aminolevulinic acid (ALAPDT) treatment of cutaneous squamous cell carcinoma in-situ (SCCIS) with blue light.
Data collection and statistical analysis was performed on the demographics, clinical
history, and procedure details of patients who have biopsy-confirmed diagnoses of
SCCIS treated initially with PDT. Treated lesions had a complete response rate of 55%
(39/71) after initial PDT treatment. 83% (52/63) of lesions had a complete response with
1-2 cycles of PDT. Age and large size (>2 cm) were inversely correlated with complete
initial response. The mean disease-free survival was 13.379 months (standard deviation
of 2.0 months, C.I. [9.477, 17.280], 41 observations) for lesions receiving 1 PDT
treatment, and 13.590 months (standard deviation of 2.3 months, C.I. [9.072, 18.107], 23
observations) for lesions receiving 2 treatments. There was no statistical difference
between 1 and 2 PDT treatments in terms of disease-free survival function. Recurrence
rates were 12% (4/33) following 1 PDT treatment and 32% (6/19) following 2 PDT
treatments. Depending on clinical details, PDT may be an appropriate choice of treatment
for SCCIS.

SCCIS and skin cancers arise when cancer-causing mutations develop and
accumulate in keratinocytes. The majority of skin cancer cases are attributed to mutations
caused by ultraviolet (UV) radiation. Specific UV-induced mutations in tumor-suppressor
genes have been documented in normal skin, skin cancer precursors, and SCC lesions.
This study aims to develop a system to quantify and characterize the mutations in TP53,
Hras, Nras, Kras, CDKN2a, Notch1, Notch2, Notch3, Fat1, Fgfr3, Knstrn, and Braf in
clinically and histologically normal skin, and relate this data to level of sun damage using
next-generation sequencing. This project is still in process. At this point, primers have
been designed to be used in concert with Illumina, Inc.’s extension-ligation system to
target a total of 59,547bp within the aforementioned genes, and sequencing of an initial
cohort of patient samples has been completed with a total sequence size of 1.54E11bp
with 72.26% high-quality sequence. Ongoing work of sequence analysis will quantify the
mutation burden in these samples and correlate these results to skin cancer history.
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INTRODUCTION

Skin Cancer
Skin cancer is the most commonly diagnosed cancer in the United States[1] and the
most common malignancy worldwide[2, 3]. The incidence of both non-melanoma skin
cancer (NMSC) and melanoma is increasing[1]. 99% of NMSC cases are basal cell
carcinoma (BCC) or cutaneous squamous cell carcinoma (SCC).[4] One set of estimates
is that the total number of NMSCs in the US population in 2012 at 5,434,193 and the
total number of persons in the United States treated for NMSC at 3,315,554, with a BCC
to SCC incidence ratio of approximately 1 based on the Medicare fee-for-service
population.[5] In contrast, previous studies and multiple previous sources have reported
that BCC is the most common type of NMSC and occurs at an approximately 4:1 ratio to
SCC incidence. [6] A different sources states the average annual number of adults treated
for skin cancer increased from 3.4 million in 2002-2006 to 4.9 million in 2007-2011
(p<0.001). During this period, the average annual total cost for skin cancer increased
from $3.6 billion to $8.1 billion (p=0.001), representing an increase of 126.2%, while the
average annual total cost for all other cancers increased by 25.1%. During 2007-2011,
nearly 5 million adults were treated for skin cancer annually, with average treatment costs
of $8.1 billion each year. [1]
Since risk of skin cancer correlates with increasing age, the aging baby boomer
population may play a contributory role to changes in skin cancer rates.
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Cutaneous squamous cell carcinoma (SCC) is the second most common type of
skin cancer. Its incidence among the US Medicare fee-for-service population in 2012 is
estimated to be 1,027,700, and while both BCC and SCC are increasing in incidence,
SCC rates may be increasing at a faster rate than BCC.[5] A study of South Florida
patients treated in 1996 for NMSC yielded a higher prevalence of SCC than BCC,[7] and
a survey of Mohs fellowship directors showed an increasing ratio of SCC to BCC treated
by Mohs.[8]
Environmental risk factors for skin cancer include exposure to ultraviolet (UV)
radiation, chemical exposures, immunosuppression, immunocompromised conditions,
chronic skin injury or irritation, and human papillomavirus (HPV) infection. Genus β
human papillomavirus infection has been associated with SCC but not BCC.[9] NMSC is
associated with chemical exposures to “pesticides, asphalt, tar and polycyclic aromatic
hydrocarbons, and they typically result in SCC”. [10] Arsenic is associated with both
SCC and BCC. [11] Immunosuppression, such as in organ transplant recipients, and
immunocompromised states, such as HIV infection, are also associated with increased
risk of skin cancer, especially SCC, and the majority of SCCs in organ transplant
recipients were found to contain HPV DNA[10]. Ionizing radiation has been implicated
in SCC pathogenesis, which also means increased risk for airline pilots and other
occupations involving increased exposure to ionizing radiation.[10]
UV radiation is the best known environmental risk factor for skin cancer, and in
the northern hemisphere, decreasing latitude consistently correlates with increasing rates
of skin cancer. [10] (Intensity of UV radiation generally increases as one gets closer to
the Equator.) In SCC, there is a fairly straightforward correlation between cumulative
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long-term UV dose and cancer risk, whereas BCC risk correlates more linearly with
number of severe sunburns. [12] In Caucasians, skin cancer also tends to develop in areas
with large amounts of sun exposure, with the head and neck as the most common sites of
SCC[13, 14] and over 80% of NMSCs developing on the head, neck, and hands.[15] On
the other hand, melanoma’s most common anatomic sites vary by age group and gender,
with melanoma occurring most commonly on the trunk in men and on the lower
extremities followed by the trunk in women, but occurring most commonly on the head
and neck in patients who were 80 years old or older. This may be related to cultural
aspects of skin exposure that vary by age and gender.[15, 16] Furthermore, in the United
States, where drivers sit on the left side of cars and therefore receive more UV radiation
to the left side of their body, skin cancers are more likely to occur on the left than the
right. [17]
Given the relationship between UV radiation and skin cancer, depletion of the
ozone layer, an atmospheric layer that absorbs the majority of UV-B radiation from the
sun, in recent history[18] may be contributory to the rise in skin cancer incidence.
Not only does UV radiation occur during typical outdoor activities, it can also
occur during tanning lamp usage, therapeutic UV exposure, and occupational work like
agriculture. Intentional tanning has been shown to increase the risk of both BCC and SCC
[19]. Psoralen and ultraviolet A (PUVA) therapy is used to treat several skin conditions,
such as atopic dermatitis, psoriasis, graft-versus-host disease, and vitiligo. Long-term
PUVA therapy has been found to correlate with SCC risk in a dose-related manner. [20]
Agricultural labor has also been associated with increased skin cancer risk. [10]
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Humans have some natural protection against UV radiation in the form of
melanin. Melanin is a naturally-occurring pigment in multiple organs and species,
including human skin, and is produced by specialized cells called melanocytes which
reside in the epidermis, among other places. It is produced and contained within
organelles called melanosomes, which are then transported to nearby keratinocytes. [21]
Epidermal melanin provides some protection against UV-induced DNA damage by
partially filtering out UV radiation, and since darker skin tends to have more melanocyte
activity and larger, more dispersed, and more melanized melanosomes than lighter skin,
dark skin is more protective against UV-induced skin damage than paler skin. [22]
Conversely, since UV-B rays are also necessary for vitamin D synthesis, darker-skinned
people are more at risk for vitamin D deficiency than their lighter-skinned counterparts at
the same latitude.[23]
Since susceptibility to UV-induced skin damage is dependent on intrinsic
phenotypic characteristics, skin cancer, like many other cancers, has genetic risk factors
as well. Light skin, red hair and to a lesser extent blonde hair, poor ability to tan,
freckling, and by extension Caucasian race are well-known risk factors for both NMSC
and melanoma.[24, 25] Certain MC1R alleles are associated with fair skin and red hair,
which means they are also associated with increased melanoma and NMSC
risk.[10] ”Epidermal melanin in blacks filters twice as much ultraviolet B
(UVB) radiation as does that in Caucasians,”[26] and a greater dose of UV radiation is
required to produce erythema in black skin than in white.[21] In Hawaii, the incidence
proportion of ethnic Japanese who develop NMSC is much lower than the incidence
proportion for whites living in the same area. [27] Given the relationship between skin
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color, tanning ability, and likelihood to develop sunburns, the Fitzpatrick skin type or
phototype classification scheme was developed and adopted to characterize individuals’
skin based on these characteristics, with lower numbers corresponding to generally
lighter skin and greater likelihood of developing sunburns instead of tanning.[28]
Oculocutaneous albinism, an autosomal recessive condition which involves
defective melanin synthesis, naturally also leads to an increased risk of melanoma and
NMSC, especially SCC, compared to normal individuals.[10]
While skin pigment helps prevent DNA damage from UV rays, DNA repair
mechanisms guard against skin cancer by repairing DNA after receiving UV-mediated
damage.
UV radiation induces genetic mutations in the cells of sun-damaged skin
primarily through the process of generating pyrimidine dimers in DNA, and to a lesser
extent double-stranded breaks. Left uncorrected, these changes can be mutagenic or
carcinogenic by leading to errors in DNA replication and transcription. However,
numerous DNA repair mechanisms exist to combat this. Nucleotide excision repair is the
main repair mechanism for UV-mediated damage involved in mammals, wherein
thymine dimers are removed and then replaced on the DNA strand by polymerase and
ligase.[29] In plants and some other organisms, photolyases can repair pyrimidine
dimerization by harnessing the power of light to directly break intradimer bonds.[30]
However, in an autosomal recessive condition known as xeroderma pigmentosum,
affected individuals have defective nucleotide excision repair enzymes. As a result,
individuals under 20 years of age with xeroderma pigmentosum had over an 1000-fold
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increase in rates of melanoma, BCC, and SCC compared to the general US
population.[31]
Other genetic conditions that lead to an increased risk of skin cancer include
dystrophic epidermolysis bullosa, which involves mutations in type VII collagen and is
associated with SCC; Gorlin syndrome, also known as nevoid basal cell carcinoma
syndrome, which involves a PTCH mutation and, as the name suggests, BCC; Bazex
syndrome, which is associated with BCC; and Rombo syndrome, which is associated
with BCC. Epidermodysplasia verruciformis is a rare inherited disorder that involves
widespread cutaneous HPV colonization and an increased risk of SCC. [10]
Given their decreased susceptibility to UV-induced skin damage, the
epidemiology of skin cancer in darker-skinned individuals is quite different. Instead of
exposure to UV radiation, the most significant risk factor for SCC may in fact be chronic
skin irritation and injury. [10] However, UV radiation still has an impact on skin cancer
risk in individuals of color. Given differences in UV intensity and outdoor activities,
people of Japanese ethnicity in Japan and Hawaii exhibit different rates of skin
cancer.[32] UV radiation exposure has also been shown to have a significant effect on
BCC risk in blacks. [26, 33]

Actinic keratosis and squamous cell carcinoma in-situ
Precursors to SCC include actinic keratosis and squamous cell carcinoma in-situ
(SCCIS), also known as Bowen’s disease (BD).
Actinic keratosis (AK) is a premalignant lesion containing atypical keratinocytes
that are confined to the epidermis with no risk of metastasis, but it has the capacity to
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transform into SCC.[10] The risk of AK evolving into SCC is estimated to be 0.075–
0.096% per lesion per year.[10] Since the risk factors for AK are shared with risk factors
for skin cancer, they can serve as markers for a high risk of developing SCC.[34] About
12% of Americans are estimated to have actinic keratoses.[35] Clinically, they tend to
present as scaly erythematous papules varying in size.[10]
Squamous cell carcinoma in-situ (SCCIS), also known as Bowen’s disease (BD),
is a precursor to invasive SCC and refers to SCC that is confined to the epidermis.[36]
Clinically, it can present as an erythematous plaque or patch with scale.[10, 36] SCCIS
lesions are thought to have a 3-5% risk of progression to invasive SCC.[37] Treatment
options for SCCIS include simple excisional surgery, Mohs surgery, cryotherapy,
imiquimod, 5-fluorouracil, electrodessication and curettage, and photodynamic therapy
(PDT).[36-38] Surgery has been reported to have low recurrence rates of 4.6%-8.3%.[3942] Imiquimod, a topical immune response modifier, has been reported to have complete
response rates of 93%[43] and 75%.[44] In the randomized controlled trial demonstrating
75% complete response, no recurrences occurred within the 9mo follow-up.[44]
Fluorouracil, also known as 5-FU, is another topical treatment and has reported complete
response rates of up to 92%[43] and 67%[45].

Tumorigenesis and Field Cancerization
During tumorigenesis, driver mutations in oncogenes accumulate, which leads to
expansion of mutated clones and positive selection for clones with more malignant
potential.[46, 47] These driver genes confer a selective advantage to the cells that have
them.[46] In order for this model to work, the accumulation of random somatic mutations
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in normal non-cancerous cells must be occurring in order for the accumulation of cancerpromoting mutations and malignant transformation to be possible.[48] Leukemiaassociated somatic mutations have been shown to accumulate with age in blood cells in
individuals without overt hematological disease.[49]
Specific mutations in tumor-suppressor genes have been documented in normal
skin, actinic keratoses, and SCC lesions. Mutations in TP53, a tumor suppressor gene that
plays a crucial role in the development of SCC, have been found in histologically and
clinically normal skin[50, 51] and actinic keratosis,[52] a precursor of SCC. Up to 4% of
normal skin contains keratinocytes with TP53 mutations, and the mutation burden
corresponds to actinic damage.[50] A high burden of Notch1, FAT1, Kras, Nras, and
Hras mutations associated with skin cancer has also been found to exist in normal sunexposed skin, and normal keratinocytes undergo pervasive positive selection for these
mutations.[51] As part of the phenomenon known as “field cancerization,”[53] lesions of
SCC are then more likely to develop in these “fields” of genetically-altered skin.[54]
Several mutations have been characterized in SCC, including functionally
significant mutations in the tumor suppressor genes TP53, Notch1, Notch2, and
CDKN2A.[55-57] SCC lesions have been reported to have mutation burdens of 63-95%
in TP53,[56, 57] 82% in Notch1 and/or Notch2,[57] and 28% in CDKN2A. [57]
TP53, for instance, is a tumor suppressor gene nicknamed “the guardian of the
genome” which plays multiple critical roles inside the cell when DNA damage is
incurred. [58] As a tumor suppressor gene, loss-of-function (LOF) mutations of TP53 is
generally associated with cancer, in contrast with oncogenes, where gain-of-function
(GOF) mutations are associated with cancer.[59] It is located on the short arm of
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chromosome 17 at 17p13.1 in humans. The gene is 19,149bp long with 11 exons, and is
highly conserved across multiple species. [60, 61] p53, the protein encoded by TP53, is
activated in response to DNA damage, oxidative stress, or other forms of cytotoxic
stress.[62]
TP53 mutations have been implicated in multiple cancers, such as cutaneous SCC, BCC,
melanoma, colon, lung, esophagus, breast, liver, brain, reticuloendothelial tissues, and
hematopoietic malignancies.[63] Most functional TP53 mutations occur in the DNAbinding domain, which affects p53’s ability to activate downstream genes and induce cell
cycle arrest or apoptosis.[62] Without proper p53 function, cellular mutations can rapidly
accumulate without cell cycle arrest, which can ultimately lead to uncontrolled
proliferation if the right set of mutations occur. This phenomenon occurs in Li-Fraumeni
syndrome, a hereditary predisposition to cancer, including melanoma, involving
autosomal dominant inheritance of a mutated TP53 allele.[64]
Mutated keratinocytes in a field of damage appear to be precursors to SCC and
SCC in situ. Many patients develop multiple primary lesions within the same field. Field
treatment like PDT targets both the cancer and the surrounding field, so theoretically
PDT may be more effective at preventing subsequent cancers than lesion-based therapy,
such as surgery.
Although there is scientific awareness that field cancerization exists, laboratorybased methods of quantifying the mutation severity or the cancer risk of a field of skin, or
of tracking response to therapy, do not exist for clinical use. Mutation burden analysis
may be a useful clinical tool for these purposes.
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Photodynamic Therapy (PDT)
Photodynamic therapy (PDT) is a treatment comprised of three necessary
components: a photosensitizer, visible light, and oxygen, allowing for the generation of
reactive oxygen species. The therapy involves two distinct stages: the first stage is
application of the photosensitizer in the absence of light, and the second stage is the
application of light. It has been utilized in a large number of dermatologic and oncologic
conditions and in various anatomic sites, including skin conditions such as psoriasis,
actinic keratosis, squamous cell carcinoma in-situ, basal cell carcinomas, as well as for
cosmetic purposes; tumors of the oral cavity, pharynx, and larynx; Barrett’s esophagus;
cholangiocarcinoma; peritoneal carcinomatosis or sarcomatosis; prostate cancer; bladder
cancer; and non-small cell lung cancer (NSCLC). [65, 66]
The use of light therapy dates back to the ancient Egyptians, who would treat
vitiligo with sunlight and the oral ingestion of a plant that contained psoralen, a
compound still used in modern medicine in combination with UV light to treat a variety
of dermatologic conditions.[67] The history of contemporary phototherapy starts with
Finsen using filtered light from a carbon-arc lamp to treat lupus vulgaris, a skin infection
with M. tuberculosis, for which he was later awarded the Nobel Prize in Physiology or
Medicine in 1903.[68] Shortly after, a German team discovered that acridine was a
photosensitizer and coined the term “photodynamic effect,” which they later used to treat
solid tumors in one of the first applications of photodynamic therapy to cancer. [69-72]
Photodynamic therapy fell out of favor until Dougherty started clinical trials of
PDT with hematoporphyrin derivative (HPD), a combination of porphyrins, as the
photosensitizer in 25 patients with BCC, melanoma, chondrosarcoma, colon
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adenocarcinoma, prostate cancer, mycosis fungoides, endometrial carcinoma, breast
cancer, angiosarcoma, or SCC in 1978. The trial was successful and resulted in a
commercially available photosensitizer. [69, 73] HPD was given the brand name
Photofrin, and was “first given approval in 1993 by the Canadian health agency for use
against bladder cancer.”[74] Approval in more countries and for usage against more
cancers quickly followed.[74] Even today, Photofrin is the most widely-used
photosensitizer.[65]
The next major breakthrough in PDT research was the discovery that 5aminolevulanic acid (ALA or 5-ALA) was a precursor of protoporphyrin IX (PPIX),[65]
which opened the door for second-generation photosensitizers. In the heme biosynthetic
pathway, ALA can be converted to PPIX and then ultimately heme. Normally, excess
heme then provides negative feedback by inhibiting ALA synthase, the enzyme that
synthesizes ALA, to prevent the accumulation of protoporphyrin and other intermediates.
However, the addition of exogenous ALA bypasses this step, which then leads to an
accumulation of PPIX within the cell because the final enzyme in the pathway,
ferrochelatase, is rate-limiting.[66] In ALA-PDT, the pro-drug ALA is administered to
patients and then converted to the photosensitizer PPIX by the patient’s own cells.
Methyl aminolevulinate (MAL) is an esterified and therefore more lipophilic form
of ALA, which allows topical MAL to penetrate skin more readily than ALA and achieve
a higher intracellular concentration of PPIX.[75] It is used to treat similar conditions as
ALA-PDT, and is commonly used in Europe, whereas ALA is used more commonly in
the US.[66]
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Photosensitizers such as PPIX are molecules that can absorb units of light energy,
or photons, at specific wavelengths and then utilize this energy to undergo reactions with
other molecules to eventually generate reactive oxygen species (ROS) and radicals,
which then can inflict cellular damage. [74]
After absorption of a photon, the photosensitizer is excited to a singlet state, and
then can rapidly transition directly to the ground state or drop to a less excited triplet state
before dropping back to the ground state. Prior to returning to the ground state, the
photosensitizer can generate phototoxicity through two different types of processes. In
Type I processes, the photosensitizer, in its singlet or triplet state, interacts directly with a
substrate via a reduction-oxidation (redox) reaction to generate a free radical (also known
as “radical”), which can then interact with molecular oxygen to generate various reactive
oxygen species (ROS). In Type II, the excited triplet photosensitizer directly undergoes a
redox reaction with molecular oxygen to generate ROS. The Type II process
predominates in the use of photodynamic therapy to generate cellular damage, although it
is possible for both pathways to be at play in PDT. [74]
The ideal characteristics of a photosensitizer will vary depending on the context
and therapeutic intent, but there are properties that are endorsed by multiple, although not
necessarily all, sources:
1. Strong absorption in the visible or infra-red spectrum. Light at these
wavelengths is readily available and has no tissue toxicity. Longer wavelengths in the
600-800 or 600-850nm range (red to deep or infra-red spectrum) may be superior for
some applications.[65, 74] Light at these wavelengths can penetrate deeper into
tissue,[74] but this feature is usually endorsed by sources referring to the usage of red
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light for PDT, so it may be less relevant if another wavelength is being used and the main
characteristic desired is for strong absorption in the relevant wavelength. However, light
at longer wavelengths will likely not generate enough energy for the photochemical
reaction.[65]
2. Have minimal dark toxicity. In other words, the ideal photosensitizer should
not exhibit cytotoxicity in the absence of light.[65, 74] This allows the provider to have
greater control over the effects of PDT by manipulating the amount and type of light
provided.
3. Rapidly clear from the body. This should help decrease cytotoxicity. For
instance, one of the most common adverse effects of PDT is photosensitivity in normal
tissue, so rapid clearance could help reduce patient discomfort or inconvenience.[69]
4. For practical purposes in terms of production and clinical availability, ideally
the photosensitizer would be a) a single well-characterized compound that b) has a simple
or reliable means of production and c) a stable and reproducible formulation.[69, 74]
Additionally, “The drug itself should be easily shipped and transported in a stable state
and if needed to be reconstituted, this process should be possible by trained pharmacists
without the requirement of specialized laboratories or tools. The administration of the
drug itself should be possible in an outpatient setting.”[69]
5. Selectively target or preferentially accumulate in diseased tissue over normal
healthy tissue. [69, 74] During the topical application of ALA-PDT to treat neoplastic
skin lesions, ALA may more readily penetrate tumor cells due to a disrupted stratum
corneum, but this is not the main reason for its selective effect.[75, 76] Neoplastic cells
are thought to have increased enzyme activity of porphobilinogen deaminase (PBGD),
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which synthesizes a precursor of PPIX, and decreased ferrochelatase activity, which
means PPIX accumulates more rapidly in diseased skin than normal skin.[75, 77, 78]
6. Be deliverable to the target tissue. One author suggests solubility in biological
media for intravenous (IV) delivery,[74] while another suggests amphilicity- the dual
properties of hydrophilicity for delivery through the bloodstream and lipophilicity to
enter the tumor.[69] In the case of topical PDT for malignant or pre-malignant lesions,
ALA’s molecular size is small enough to allow penetration of the skin, and an esterified
form of ALA, called methyl-aminolevulinate (MAL), has increased lipophilicity so it can
penetrate deeper into the skin.[66]
7. Efficiently undergo the photodynamic reaction and efficiently generate
ROS.[69, 74] Since the length of time spent in the triplet state affects the ability of the
photosensitizer to generate ROS or interact with substrate, then longer durations of the
triplet state are desirable.[74]
The majority of photosensitizers currently used in PDT have a cyclic tetrapyrrole
or derivative structure. While other kinds of photosensitizers, such as methylene blue,
acridine, and rose bengal, also exist, photosensitizers with a cyclic tetrapyrrole structure
are used more predominantly in modern times because their structure is similar to
endogenous porphyrins and therefore have low dark toxicity.[74] These secondgeneration photosensitizers include MAL, ALA, benzoporphyrin derivative monoacid
ring A (BPD-MA), chlorins, bacteriochlorins, expanded porphyrins, and phthalocyanine
derivatives. Further work is underway to develop third-generation photosensitizers
through metalation or coupling with targeted biological molecules.[74]
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The other important controllable component of the procedure is the light source.
For electromagnetic radiation, which includes visible light, wavelength is inversely
correlated with frequency, and since the Planck-Einstein relation states that the energy of
a photon is directly correlated with its frequency, then photon energy is inversely related
to wavelength. Above around 800nm, illumination is ineffective for PDT because it does
not provide sufficient energy to excite the photosensitizer.[65] Since electrons can only
absorb defined quantities of energy to reach an excited state, compounds will have
absorption peaks at certain wavelengths. PPIX has a maximal absorption peak in the blue
range at around 405nm[79] or 410nm[80] called the Soret band. It also has smaller
absorption peaks in the visible range, called Q bands, at 505 or 510nm (green), 540nm,
575 or 580nm, and 635nm (red) wavelengths,[69, 80, 81] ROS are generated more
rapidly at shorter wavelengths, which allows for shorter treatment times.[69] On the flip
side, longer wavelengths of light are able to penetrate tissues more deeply, and the
“optical window of tissue” is often considered 600nm-1200nm, which ranges from the
red to near-infrared portions of the electromagnetic spectrum.[65] The skin’s superficial
nature is advantageous when it comes to PDT, since it means that light penetration is less
of a concern than it may be for other bodily tissues and using shorter-wavelength higherenergy forms of light is feasible.
ALA-PDT and MAL-PDT have been used for the treatment of NMSC and other
dermatological conditions. One of the earliest clinical trials involving ALA-PDT was a
clinical trial in the early 1990s using 3-6hour incubation and 3.5 to 30min light exposure.
Preliminary results from that clinical trial showed a complete response at the 2-3month
follow-up in 72/80 (90%) BCC lesions, 6/6 lesions diagnosed either with early invasive
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SCC or SCCIS, and 9/10 AKs. 2 SCC lesions that were raised ³10mm above the surface
of the skin were unresponsive to multiple treatments, and PDT had limited usefulness in
treating the percutaneous nodules of 4 cases of metastatic breast cancer. [82] Another
1993 study using ALA-PDT with 4-8 hour incubation “observed a complete response
after a single treatment for all 9 solar keratoses, 5 of 6 early invasive squamous cell
carcinomas, and 36 of 37 superficial basal cell carcinomas. Only 1 of 10 noduloulcerative basal cell carcinomas completely resolved. Eight cutaneous metastases of
malignant melanoma were therapeutic failures.”[83]
Both MAL-PDT and ALA-PDT are frequently used to treat actinic keratosis, and
have been shown to have comparable results to other treatment modalities. Multiple
randomized controlled trials have shown that both ALA-PDT and MAL-PDT have
superior results compared to controls using a vehicle and light, with rates of complete
response of greater than or equal to 70%.[84-86] Several trials also show that MAL-PDT
can achieve similar treatment success rates as cryotherapy and 5-fluoruracil (5-FU)
treatment. Depending on the study, PDT had complete response rates of 69-91%
compared to complete response rates of 68-75% for cryotherapy, and when cosmetic
outcomes and patient comfort were examined, PDT consistently performed superiorly to
cryotherapy.[85, 87] One study that measured % reduction in lesional size instead of
complete response rate had 70% reduction in lesional area for 5-FU treatment and 73%
mean reduction in lesional area for PDT treatment.[88]
The results from a 1991-1992 phase I clinical trial using ALA-PDT to treat
SCCIS, superficial BCC, and metastatic skin lesions from breast adenocarcinoma or SCC
of the pinna were published by Cairnduff et al in 1994. This study had a complete
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response rate of 89% in 36 cases of SCCIS, 50% complete response in superficial BCC,
and poor treatment response in metastatic lesions.[89]
In the US, ALA, under the brand name Levulan, gained FDA approval for the
treatment of AKs in Dec. 1999. [90]
PDT has also been used and studied in the treatment of BCC multiple times, and it
can be an effective treatment against BCC.[91, 92] Compared to simple excision surgery,
MAL-PDT does not have a statistically significant difference in complete response rates
when treating superficial BCC, with complete response rates of 92.2% (118/128 lesions)
after 1-2 treatments of PDT compared to 99.2% (117/118 lesions) for surgery. However,
PDT performed significantly better in terms of cosmetic outcome.[93] In another study
comparing PDT and surgery for nodular BCC, ALA-PDT and simple excision surgery
had similar response rates of 94% (78/83) and 98% (86/88) respectively, but PDT had
significantly higher recurrence rates within the first 3 years at 30.3% versus 2.3%
respectively.[94] A 2012 study also found that ALA-PDT had statistically similar
response rates and recurrence rates as surgery but superior cosmetic outcomes.[95]
Compared to cryotherapy, PDT also has similar response rates, but it had 5% instead of
13% clinically obvious recurrences and performed significantly better in terms of
cosmetic outcome.[96] In contrast, a different study found that for superficial BCC,
imiquimod and 5-FU were more effective treatments than MAL-PDT.[97]
In contrast to BCC, PDT has been used much fewer times as a curative treatment
for SCC, likely because SCC is more aggressive than BCC. Several cases have been
documented of treating invasive SCC with PDT.[98, 99] Two studies have shown poor
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response rates for SCC, one with 54% (19/35) complete response rate[100] and another
with 25% (1/4) complete response rate.[81]
Since surgery performs as well or better than PDT in terms of efficacy when
treating cutaneous malignancies, PDT may be preferable in cases where cosmetic
outcome is particularly important, such as when the lesion size is large or the lesion is in
an aesthetically sensitive area, in patients who are poor surgical candidates, when lesion
size or location are contraindications to surgery, or when patient preference dictates that
PDT is attempted first.

Treatment of Cutaneous Squamous Cell Carcinoma In-Situ with PDT
Although PDT is not FDA-approved for the treatment for SCCIS, several studies
and case reports have been published about using PDT to treat SCCIS. Multiple treatment
protocols exist, so studies and clinical treatments may use a variety of incubation times
and light sources. A case report was published in 2000 in which ALA-PDT with 4-hour
incubation with 20% ALA and red and near-infrared light successfully treated SCCIS on
chronic radiation dermatitis and no recurrence was observed in 18 months of followup.[101] Then in 2001, a case series was published with 16 hour incubations with 2%
ALA and “a newly designed light-emitting diode (LED) array with a peak wavelength of
630 nm,” which is red light. The cases involved the treatment of SCCIS of the digit in 4
patients with chronic arsenicism, which resulted in 1 recurrence within the first 15-17mo
following treatment.[102] The major risk factor for SCCIS in both these cases differs
from the usual cause of SCCIS via sun exposure.
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The largest randomized controlled trial of PDT for the treatment of SCCIS
compared MAL-PDT to 5-fluorouracil treatment and cryotherapy, as well as placebo
PDT. The light source used was 570-670 nm (red light), and incubation was 3 hours with
160mg/g MAL. “The clinically verified complete response rate of lesions 3 months after
last treatment was 93% (103/111) in the methyl aminolevulinate PDT group, 21% (4/19)
in the placebo PDT group, 86% (73/85) in the cryotherapy group, and 83% (24/29) in the
fluorouracil group.” Complete response rates at 12mo were not significantly different
between PDT and 5-FU treatment, but cryotherapy performed significantly worse.
“Lesion recurrence rates 12 months after the last treatment were 15% (15/103) in the
methyl aminolevulinate PDT group, 50% (2/4) in the placebo PDT group, 21% (15/73) in
the cryotherapy group, and 17% (4/24) in the fluorouracil group.” “Cosmetic outcome
(on-site evaluation) at 3 months was clearly superior with methyl aminolevulinate PDT
compared with either cryotherapy or fluorouracil, with a good or excellent outcome in
94% (77/82) (95% CI, 86%-98%) of patients treated with methyl aminolevulinate PDT vs
66% (43/65) (95% CI, 53%-77%) treated with cryotherapy and 76% (16/21) (95% CI,
53%-92%) treated with fluorouracil; and this was maintained for 12 months.”[103]
In 2007, a group in the Netherlands compared single illumination PDT, which is a
typical single PDT treatment, against double-illumination PDT, wherein a lesion would
be illuminated with 630 nm (red) light once at 4 hours after ALA application and once
again at 6 hours after ALA application. Incubation utilized 20% ALA and lasted 4 hours.
25 lesions were assigned to each of the two treatment groups. Ultimately, the study found
that complete response rate at 12mo was higher for the 2-fold illumination group at 88%
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(22/25) as opposed to 80% (20/25), but this difference was not statistically
significant.[104]
In 2008, a series of cases from Shanghai Skin Diseases & STD Hospital was
published detailing their use of PDT for several conditions, including 13 cases of SCCIS.
Their treatment procedures varied between cases, with 3-5 hour incubations with 20% or
10% ALA, 635nm light, and 3-5 treatments for all patients. 92.3% (12/13) of the SCCIS
cases showed a complete response, and no SCCIS recurrences were reported in 12mo of
follow-up.[99]
In 2009, a study was published looking at long-term follow-up in 19 cases of
SCCIS. While the previous studies mentioned had follow-up lengths of around 18mo or
less, this study followed patients for an impressive 60mo after treatment. Lesions were
treated with 6hour 20% ALA incubation, 630nm (red) light, and 1 treatment session, and
the therapy yielded 89.5% (17/19) tumor-free survival at 3mo and 53.3% (8/15) tumorfree survival at 60mo post-treatment.[105]
This was followed in 2011 by another study looking at long-term follow-up in
PDT for SCCIS. 30 Caucasian patients with 43 lesions received 2 sessions of MAL-PDT
1 week apart, with 3 hour incubations with 160mg/g MAL and 635nm (red) light
illumination. Lesions had 100% (43/43) complete response at the 6mo follow-up, and
there was 11.6% (5/43) recurrence rate with a mean follow-up length of 50 months. Of
the 5 recurrences, 2 of them occurred in immunosuppressed patients.[106]
In 2012, a case series of 51 SCCIS lesions treated by MAL-PDT was published.
Incubation lasted 3 hours and used 160mg/g MAL, followed by illumination with 630nm
(red) light. 76% (35/46) of treated lesions had a complete response, while 5 lesions were
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not seen for a post-treatment evaluation. 12% (6/51) of treated lesions had a recurrence,
with a mean follow-up time of 17 months from biopsy acquisition.[107]
A 2015 study included 31 SCCIS lesions treated with MAL-PDT. The treatment
protocol involved incubation for at least 3 hours with 160mg/g MAL, illumination with
630nm (red) light, and 2 treatments spaced 1 week apart. At 3months post-treatment,
84% (26/31) treated SCCIS lesions exhibited a complete response. However, 53.8%
(14/26) ended up having a recurrence within a median follow-up time of 43.5 months,
with a 5-year estimated recurrence rate of 72%.[108]
In 2016, a retrospective study was published comparing the efficacy of MALPDT versus ALA-PDT for SCCIS, as well as BCC and AK. Incubation lasted 3 hours and
either involved 20% ALA or 160mg/g MAL, followed by illumination with 630nm (red)
light. If 2 PDT treatments were given, then the second treatment generally followed
within a few weeks of the first. For SCCIS, 6 lesions received 1 session of ALA-PDT
with a complete response rate of 83% (5/6), 3 received 2 sessions of ALA-PDT with a
complete response rate of 100% (3/3), 4 received 1 session of MAL-PDT with a complete
response rate of 75% (3/4), and 14 received 2 sessions of MAL-PDT with a complete
response rate of 79% (11/14). Overall, complete response rate for SCCIS lesions treated
with ALA-PDT was 89% (8/9) and complete response rate for SCCIS lesions treated with
MAL-PDT was 78% (14/18). The difference between MAL-PDT and ALA-PDT was not
statistically significant.[109]
All of these studies use red light illumination, even though MAL and ALA have
multiple absorption peaks, and incubation times last at least 3 hours but can be overnight
incubations in some cases. Most of the studies use ALA-PDT rather than MAL-PDT, and
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the number of treatments varies. Reported complete response rates are good, ranging
from 75% to 100%, although most studies had small sample sizes. However, long-term
recurrence rates may also be high. The studies that looked specifically at long-term
recurrence rates had average follow-up lengths of 43.5-60 months, with recurrence rates
of 11.6%, 54%, and 57%.[105, 106, 108] The rest of the studies described had average
follow-up lengths of 12-24 months. Cosmetic outcome appears to be very good with
PDT, which could be a reason to choose it as initial therapy despite suboptimal response
and recurrence rates.
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STATEMENT OF PURPOSE

Photodynamic Therapy for Cutaneous Squamous Cell Carcinoma In-Situ
HYPOTHESIS
1) blue light ALA-PDT has a high complete response rate in the treatment of SCCIS
2) blue light ALA-PDT has a low recurrence rate or long disease-free survival interval in
the treatment of SCCIS

SPECIFIC AIMS
1. Characterization of the clinical response rate of SCCIS lesions treated with blue light
ALA-PDT and the relationship with factor variables including patient characteristics,
lesion characteristics, and treatment procedure
2. Characterization of the recurrence rate of SCCIS lesions treated with blue light ALAPDT
a. Characterization of documented disease-free survival within the treatment field
of SCCIS lesions treated with PDT
b. Calculation of a Kaplan-Meier survival distribution function
c. Comparison of disease-free survival between lesions receiving different
numbers of PDT treatments
3. Determining the relationship between side-effects of PDT treatment and independent
variables including patient characteristics, lesion characteristics, and treatment procedure
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Mutation Burden Analysis
HYPOTHESIS
1) mutations in critical tumor-suppressor genes, namely TP53, Hras, Nras, Kras,
CDKN2a, Notch1, Notch2, Notch3, Fat1, Fgfr3, Knstrn, Braf, exist in sun-damaged but
clinically and histologically normal skin
2) the mutation burden corresponds with the level of sun damage and history of skin
cancer.

SPECIFIC AIMS
1. Develop a sequencing strategy to detect rare somatic mutations in normal skin
a. Detection of recurrent mutations in normal skin which correlate with previously
described TP53, Hras, Nras, Kras, CDKN2a, Notch1, Notch2, Notch3, Fat1,
Fgfr3, Knstrn, and Braf mutations in skin cancer
2. Comparison of mutation burden in TP53, Hras, Nras, Kras, CDKN2a, Notch1, Notch2,
Notch3, Fat1, Fgfr3, Knstrn, and Braf with clinical degree of sun damage and other
patient variables.
a. Comparison of mutations in each individual gene and the composite mutation
level in all 12 genes
b. Analysis of mutation burden in relation to patient variables such as age, gender,
biopsy site, and history of prior skin cancer (including both type and number of
prior skin cancers).
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METHODS

Photodynamic Therapy for Cutaneous Squamous Cell Carcinoma In-Situ
This was a retrospective study based on patients who had received PDT at Yale
Dermatologic Surgery between 09/2013 to 03/2017 for a biopsy-confirmed diagnosis of
SCCIS. Exclusion criteria included prior definitive treatment, such as Mohs surgery and
5-FU, for the same lesion; prior PDT for the same lesion; prior PDT in the same area as
the lesion within the past year; and lack of any follow-up visits after PDT.
Prior to application of the photosensitizer, lesions were cleaned with acetone or
isopropanol and any scale, crust, or superficial debris was removed. Crusted and keratotic
areas were treated with curettage to the level of pinpoint bleeding. One tube of Levulan ®
Kerastick ® (20% aminolevulinic acid HCl) for topical solution) was applied to the area of
each lesion. The area was then either wholly or semi-occluded with a Telfa® dressing,
Glad® Press ‘N’ Seal® wrap and an opaque covering, or TegadermTM contact bandage and
a Telfa® dressing, or left unoccluded. The medication was then allowed to incubate while
protected from light. After the specified incubation time, any bandages were removed.
Appropriate eye protection was used by the patient. The area was then treated with blue
light at a wavelength of 417nm ±5 nm using the BLU-U® Blue Light Photodynamic
Therapy Illuminator, with total fluence of 10 J/cm2 for 1,000 seconds or 16min and
40sec, apart from 1 patient who only received illumination for 4min due to side-effects.
Patients were followed up as clinically appropriate. The treatments and follow-up visits
were provided by Dr. Sean Christensen, Dr. Samuel Book, or Dr. David Leffell of the
Yale Dermatologic Surgery practice.
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We used the following search strategy to identify patients with SCC in situ treated
with PDT: Patients of Yale Dermatologic Surgery (YMG) with a diagnosis code of SCC
in-situ and a procedure code for PDT between the dates of 09/2013 and 03-2017
(inclusive) were initially collected by electronic database search Kasia Olszewski, an
administrator in the Dermatology department. Chart review was subsequently performed
by me and Dr. Christensen and only those patients with a record in Epic® of their
diagnosis of SCC in-situ by a pathologist whose SCCIS lesion(s) were treated initially
with ALA-PDT were included in the final study. A unique numerical identifier was
assigned to each patient and lesion and associated with the clinical variables listed below.
I collected de-identified data on patient age, sex, visit dates, Fitzpatrick
phototype; SCC in-situ characteristics: date of diagnosis, clinical history, lesion
site/location, lesion size/depth, pathology report including pathologic subtype, prior
treatments in same anatomic area, whether photographs were taken and appearance of the
lesion in photos; treatment history and outcomes: including treatment types and dates,
treatment protocols (incubation time, occlusion, illumination time), treatment sideeffects, adverse effects post-treatment, results post-treatment (including lesion
appearance post-treatment, tumor recurrence, or further treatments necessary and their
types, dates, and results), follow-up dates and visit notes. For selected patients,
photographic images in medical record that document tumor burden without identifying
the patient were analyzed. Patient identifying information such as name, birthdate,
medical record number or social security number, and address or phone number were not
recorded as part of the study.
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Statistical analysis was performed by me using Microsoft Excel®, XLSTAT®, and
Stata®. Since patients may receive more PDT treatments long after their initial sequence
due to a recurrence, for all analyses that required the number of PDT treatments, I used
all PDT treatments that had been administered within a year of the previous PDT
treatment, excluding PDT treatments that were administered after recurrence had
occurred or after another form of treatment had been used, and referred to PDT
treatments that fit these criteria with the phrase “consecutive treatments.”
I used a contingency table and Fisher t-test to compare complete response rate
between 1 consecutive PDT treatment and 2 consecutive PDT treatments. Since all
lesions had to receive at least 1 PDT treatment according to our inclusion criteria, all
lesions with information on response after first PDT treatment were included in the
analysis of initial response to PDT treatment. Logistic regression was used for this
analysis because the dependent variable was binary and the output of logistic regression
is constrained to lie in the interval [0,1]. Lesions without follow-up data after the latest
consecutive treatment were excluded as missing data. Missing variables were excluded
from the regression instead of replaced with other values.
For disease-free survival analysis, patients were grouped according to number of
consecutive treatments. Groups had mutually exclusive patients, and whether lesions had
a complete or incomplete response to previous treatments did not matter for the survival
analysis—only the lesion field’s status after the latest treatment that met all above criteria
did.
Disease recurrence or persistent disease were scored as event occurrences on the
first date after all consecutive PDT treatments that disease was documented in the
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medical record. Disease recurrence referred to documented disease after a documented
complete response to treatment, whereas persistent disease did not involve a documented
complete response to treatment. Since a lesion is only at risk for recurrence if it had a
complete response, recurrence rate was defined as number of documented recurrences
divided by the number of lesions that had had a complete response. If a lesion did not
have a complete response to treatment, then for the survival analysis, it was noted as
having an event occurrence on the date of its follow-up visit and disease-free during the
time period between receiving PDT treatment and its follow-up visit. This holds true even
if a lesion that had persistent disease after PDT treatment was then treated with another
modality, such as liquid nitrogen or Mohs surgery, and exhibited a complete response to
that treatment.
Since PDT treats an entire field and not just a specific lesion, an occurrence of
new SCCIS within the same treatment field, even if it was not a recurrence of the
previous SCCIS lesion, was marked as an event occurrence and equivalent to a
recurrence for the survival analysis. Lesions that were disease-free and had no recurrence
by the end of follow-up were labelled as censored on the last date of follow-up they were
documented to be disease-free.

Mutation Burden Analysis
In order to study the mutation burden of actinically damaged skin, we will be
using the techniques of punch biopsy, DNA extraction, PCR amplification, Illumina
TruSeq Custom Amplicon® amplification, Illumina® next-generation sequencing, and
DNA sequence analysis.
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First, Dr. Christensen, Dr. Book, and Dr. Leffell collected discarded patient skin
samples obtained during their surgical treatment of skin lesions. These discarded skin
samples were obtained from clinically normal skin adjacent to a completely excised skin
cancer. Each sample was categorized by Dr. Christensen as to the degree of clinical
actinic damage.
Next, I took multiple punch biopsies ranging in size from 1mm to 4mm from the
areas of normal skin in the discarded biopsy samples to compare DNA yields. Initially,
1mm punch biopsies were obtained, but based on DNA yield, subsequently 2mm punch
biopsies were obtained.
I performed DNA extraction on the pooled punch biopsies via the Qiagen ®
QIAamp® kit or phenol-chloroform extraction with ethanol precipitation, then performed
PCR amplification on the extracted DNA samples for TP53 and HRAS sequences to
check DNA quality. We originally planned to use long-run PCR to amplify target genes,
but this was unsuccessful.
The Illumina® TruSeq Custom Amplicon® system was used for library
generation and sequencing. In this system, custom-designed oligo probes hybridize on the
same strand to flanking regions of interest in unfragmented genomic DNA. Next,
extension-ligation will occur between the custom probes across regions of interest.
Unlike PCR, these amplicons would not serve as templates for subsequent rounds of
amplification. PCR is then performed to add indices and sequencing primers to the ends
of these amplicons, resulting in a tagged amplicon library ready for cluster generation and
sequencing.
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Dr. Christensen and I designed amplicons for the exons and 5’ UTRs of TP53,
Hras, Nras, Kras, CDKN2a, Notch1, Notch2, Notch3, Fat1, Fgfr3, Knstrn, and Braf,
whose mutations are associated with skin cancer, and VHL as a control. We anticipate
that we will be able to reliably detect mutations present at a frequency as low as 1% of
the total input DNA based on the following calculation: Assuming 50% of reads are highquality and able to be mapped to target regions, the Illumina HiSeq2500® sequencing
machine has the capability to sequence 300 million reads at 150bp per read. Given our
total target size of 59,547bp, this leads to a depth of sequencing of 23,616x per bp. The
Illumina® HiSeqXTen® sequencing machine has even greater sequencing capability at 1
billion reads with 150bp per read, which leads to a calculated depth of sequencing of
78,719x.
Next-generation DNA sequencing via the Illumina® GA/HiSeq® system will be
performed on the amplicons using the HiSeq2500® or HiSeqXTen®. In Illumina®
sequencing, DNA molecules from the PCR products will be bound to primers on a slide
and amplification will be performed to produce clusters of clonal DNA fragments, which
are then linearized into single-stranded DNA templates.[110] These multiple clusters
allow for the massively parallel process of sequencing by synthesis, wherein
fluorescently-labeled nucleotides (ddATP, ddGTP, ddCTP, ddTTP) are added one at a
time to the fragments and the fluorescent signatures are simultaneously recorded.[110]
Mei Zhong is performing the library generation and the sequencing. Software for analysis
then matches the sequence reads against known genomic sequences.[110] Computerbased analysis of the DNA sequencing results will eliminate irrelevant sequences, such as
primer-dimers and other non-genomic DNA, and sequences of other genes. Resulting
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sequence reads will be evaluated for the frequency of functionally significant mutations
compared to silent mutations and wild-type sequences of these genes, which will then be
analyzed for a correlation with the clinical degree of sun damage and number of prior
skin cancers in patients from whom the biopsies were obtained. This analysis will be
done by me and Dr. Sean Christensen.

32

RESULTS

Photodynamic Therapy for Cutaneous Squamous Cell Carcinoma In-Situ
62 patients, with a total of 74 unique lesions, who met our inclusion criteria were
included in the study. Most patients with multiple PDT-treated lesions had them all
treated during the same office visit, while 2 patients with multiple lesions had initiated
PDT treatment for each lesion on separate dates. 51 patients had 1 lesion each, 10
patients had 2 lesions each, and 1 patient had 3 lesions. There were 31 male and 31
female patients, with an average age of 78 for both male and female patients, ranging
from ages 52-98 years old for women and 50-94 years old for men. All patients with a
documented Fitzpatrick phototype had one between 1-3, with 17 patients with phototype
1, 39 with phototype 2, 4 with phototype 3, and 2 patients whose phototypes were not
recorded. (Table 1).
19 lesions were located on the scalp, 2 were on the ear, 42 were located
somewhere on the face, 1 was on the neck, 1 was on the chest, 5 were located on the
upper extremities, and 4 were located on the lower extremities (Table 2). 38 lesions were
treated with only 1 cycle of PDT at this practice, 26 were treated with 2 cycles, and 10
lesions required treatment with more than 2 cycles in total (Table 3). However, many of
the subsequent treatments occurred much later or were in response to recurrences. For
instance, of the lesions that received 2 cycles of PDT, 2 of those received their second
treatment after recurrence.
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Number of patients:

62

Number of lesions:

74

Female

Number of patients with separate lesions
treated at the same time with PDT:
Number of patients with separate lesions
treated at separate times with PDT:

31

Male

31

Age
50-59
60-69
70-79
80-89
>=90

3
8
3
10
7

Age
50-59
60-69
70-79
80-89
>=90

4
4
7
13
3

Age range

52-98

Age range

50-94

Patients with 2
lesions:

10

Patients with 1 lesion:

51

Fitzpatrick
phototypes:
1
17
2
39
3
4
unknown
2
Table 1. Patient demographics
Scalp
Ear
Face
Neck
Chest or extremities
Table 2. Lesion sites

19
2
42
1
10

Patients
with 3
lesions:

9
2

1
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Lesions treated with 1 cycle of PDT (prior to any recurrence):
Lesions treated with 2 cycles of PDT:
Lesions treated with 3 or more cycles of PDT:

38
26
10

Lesions with complete response after 1 treatment:
Lesions with incomplete or partial response after 1 treatment:
Lesions with minimal or no response after 1 treatment:
Lesions without information on response after 1 treatment:

39
28
4
3

Lesions with recurrences:
Persistent lesions:
Unclear if persistent or recurrent:
Table 3. Treatment cycle numbers, responses, and recurrences

Response to PDT vs Number of
Consecutive Treatments
100%
83%

100%

100%

83%

0.8
0.6
18%

0
complete

0
complete

not complete

complete

not complete

complete

0
not complete

0

17%

not complete

0.2

not complete

0.4

complete

NUMBER OF LESIONS

1.2
1

9
7
1

1 PDT session (40) 2 PDT sessions (23) 3 PDT sessions (3) 4 PDT sessions (1) 6 tx (1)
NUMBER OF CONSECUTIVE PDT SESSIONS

Figure 1. Responses to treatment after varying numbers of consecutive PDT sessions.
Consecutive PDT sessions here refer to all PDT sessions occurring with a <1yr gap
following the previous PDT session, prior to any recurrences that may have occurred.
Only lesions with data on their responses to treatment are depicted.
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Mean follow-up time for lesions was 12.4 months, ranging from 15 days to 36.9
months, with standard deviation of 11.7 months. Months are defined as lasting exactly 30
days for this work.
For convenience, the term consecutive will be used to refer to treatments that
occurred within 1 year of the previous treatment and did not occur after a recurrence or
other form of treatment. 41 lesions received 1 treatment, 28 received 2 treatments, 3
received 3 treatments 1 received 4 treatments, and 1 received 6 treatments (Figure 1). Of
the 41 lesions that only received 1 treatment prior to any recurrence if a recurrence
occurred, 83% (33/40) had a complete response to the treatment, 17% (7/40) did not have
a complete response, and 1 lesion did not have documentation in the medical record of
the type of response to treatment. For 28 lesions receiving 2 consecutive treatments of
PDT, 83% (19/23) had a complete response, 17% (4/23) did not have a complete
response, and 5 did not have a type of response documented. There is no statistically
significant difference between complete response rates from 1 PDT treatment and 2 PDT
treatments, with a p-value=1.0 according to Fisher’s exact test with a 2x2 contingency
table (Figure 2). The remainder are 3 lesions that received 3 consecutive treatments, 1
lesion that received 4 consecutive treatments, and 1 lesion that received 6 consecutive
treatments. All of these had complete responses. Overall, 83% (52/63) of lesions had a
documented complete response with 1-2 cycles of PDT. (Figure 1).
Of all the lesions that had documentation on their response to initial PDT
treatment, 55% (39/71) of lesions had a complete response after 1 PDT cycle, 39.4%
(28/71) had a partial response after 1 cycle, and 5.6% (4/71) lesions had minimal
responses after 1 cycle (Figure 3). 5 lesions with a complete response after initial
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treatment were treated with an additional PDT session despite not having a recurrence in
the interim. 3 lesions in 3 different patients did not have sufficient information in their
medical record for us to determine the response to initial PDT, but 2 of them received a
second PDT treatment had had complete responses to that and the other patient returned 1
year later to receive Mohs surgery on this lesion site. Of the lesions that were
documented to not have a complete response after 1 cycle of PDT, 1 lesion was treated
with Mohs surgery, 3 have documentation suggesting that eventually the lesion resolved
without further treatment, 2 received no further treatment or follow-up after the initial
follow-up assessment, 1 had no further treatment and no further documentation regarding
status of the lesion site (partly due to a patient request limiting the exam), and 25 patients
then underwent a second round of PDT. 5 of these patients did not return for follow-up
after the second PDT session, and 65% (13/20) of those who did had a complete response
after 2 rounds of PDT. Of the 7 that did not have a complete response even after 2 rounds
of PDT, 3 lesions were treated with more PDT and eventually had a complete response.
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Complete
Response

Not Complete
Response

1 treatment

33

7

40

2 treatments

19

4

23

52

11

63

Table 2. Contingency table for number of consecutive PDT treatments and response to
treatment.

Initial Treatment Response for all Lesions
60%

55%

50%
39%

40%
30%
20%

6%

10%
0%
Complete Response

Partial Response

Minimal response

Initial Treatment Response

Figure 3. Initial treatment response for all lesions. % of all lesions with documented
complete, partial, and minimal responses after first treatment.
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A logistic regression model for complete response to initial PDT treatment
analyzing various patient, lesion, and treatment factors was found to be statistically
significant. The pseudo R2, which measures goodness of fit and generally ranges from 0
to 1, was 0.5629 for the model. The factors that were significantly associated with a
complete response after initial PDT treatment were age and large size. A lesion was
considered large if it had any size measurements of at least 2cm, appeared to be larger
than 2cm in clinical photos when measurements were not available, and/or was described
as “large” in a note without specific measurements being given. The odds ratio of
0.0186913 for lesions of large size to have a complete initial response indicates that all
else equal, lesions that are large have significantly worse odds to have a complete initial
response than lesions that are not. The odds ratio of complete initial response and age is
also less than 1, which means that increasing age is negatively correlated with likelihood
of a complete response after initial PDT treatment. Other factor variables, such as sex,
phototype, presence of clinical residual lesion during treatment, lesion site, occlusion,
incubation time, presence of erythema, and presence of pain, were not found to be
statistically significant, and the odds ratios of certain skin types and lesion sites were
empty due to insufficient data points for those. By nature, one variable in each qualitative
category needed to be designated a dummy variable and did not have calculations. (Table
4).
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Likelihood of complete response after first PDT treatment
Pseudo R2 for overall regression model
0.5629
P-value for overall regression model

<0.0001

Independent variable
Male sex

Odds ratio
1.21434

P-value
0.871

Age

.9071233

0.038

Fitzpatrick phototype
1
2

(dummy variable)
1.73871

0.660

.147573,
20.48553

.1648968,
14.28167
.0007888,
.4429009

3

95% C.I.
.1155304,
12.76392
.8271304,
.9948524

1 (empty)

Presence of clinical residual lesion

1.534601

0.707

Large size

.0186913

0.014

Scalp
Ear
Face

(dummy variable)
1 (empty)
4.794044

0.224

.3827114,
60.0527

Neck
Chest or extremities

1 (empty)
4.314282

0.498

.0626494,
297.0982

Occlusion during incubation

5.30028

0.264

Incubation time (hours)

3.338785

0.228

Presence of erythema

2.909452

0.367

Presence of pain

1.834726

0.635

.28346,
99.10734
.4693498,
23.75091
.2854477,
29.65485
.1502722,
22.40081

Lesion site

Table 4. Logistic regression model for complete response after 1 PDT treatment.
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Patients’ reports of side-effects of pain and erythema were significantly correlated
with incubation time and with presence of erythema or pain, respectively. The logistic
regression for pain as a dependent variable had a P-value of <0.0001 and pseudo R2 of
0.5130 for the overall model (Table 5). The logistic regression for erythema as a
dependent variable had a P-value of 0.0006 and pseudo R2 of 0.3855 (Table 6).
Incubation time in hours with ALA had a statistically significant relationship with both
pain and erythema, with an odds ratio of 11.19503 with pain and of 4.110301 with
erythema, meaning that longer incubation times are likely to cause increased pain and
erythema. Pain and erythema also appears to correlate positively and significantly with
one another, with presence of erythema as a factor variable having an odds ratio of
35.4397 with pain as the dependent variable, and presence of pain as a factor variable
having an odds ratio of erythema of 8.384352. In the logistic regression model for pain as
a dependent variable, age approaches near significance as a factor variable, with a pvalue of 0.093 and odds ratio of .9252411. The factor variables of sex, age, phototype,
presence of clinical residual lesion during treatment, large size, lesion site, and occlusion
were not found to be clinically significant. (Tables 5 and 6).
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Presence of pain as a side-effect
Pseudo R2 for overall regression model
P-value for overall regression model

0.5130
<0.0001

Independent variable
Male sex

Odds ratio
.6731383

P-value
0.706

Age

.9252411

0.093

Fitzpatrick phototype
1
2

(dummy variable)
1.037243

0.977

.0862991,
12.46679

.3990067,
61.14648
.073196,
4.873563

3

95% C.I.
.0858131,
5.280255
.8449507,
1.013161

1 (empty)

Presence of clinical residual lesion

10.00121

0.213

Large size

.5972647

0.630

Scalp
Ear
Face

(dummy variable)
1 (empty)
1.313394

0.805

.1512651,
11.40384

Neck
Chest or extremities

1 (empty)
2.001625

0.725

.0421828,
94.97954

Occlusion during incubation

4.939418

0.112

Incubation time (hours)

11.19503

0.032

.5137863,
565.6868
1.230876,
101.8207

Presence of erythema

35.4397

0.040

Lesion site

Table 5. Logistic regression model for pain
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Presence of erythema as a side-effect
Pseudo R2 for overall regression model
P-value for overall regression model

0.3855
0.0006

Independent variable
Male sex

Odds ratio
1.148807

P-value
0.886

Age

1.016078

0.597

Fitzpatrick phototype
1
2

(dummy variable)
.2336373

.2198271

.0369534,
1.477166

.0989378,
3.944414
.1843299,
6.606615

3

95% C.I.
.1724624,
7.652436
.9577616,
1.077945

1 (empty)

Presence of clinical residual lesion

.6247012

.5873517

Large size

1.103538

0.914

Scalp
Ear
Face

(dummy variable)
1 (empty)
3.179493

0.211

.5185188,
19.49626

Neck
Chest or extremities

1 (empty)
2.166933

0.587

.1330546,
35.29075

Occlusion during incubation

.8318299

0.853

Incubation time (hours)

4.110301

0.033

Presence of pain

8.384352

0.018

.1194089,
5.79472
1.120249,
15.08108
1.436711,
48.92936

Lesion site

Table 6. Logistic regression model for erythema
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Survival analysis was limited by the fact that most patients did not have
systematic follow up. Patients without evidence of disease were often discharged after a
few months, since generally patients would follow-up with their primary dermatologists
in the long-term rather than with a specialized dermatologic surgery clinic. However,
patients with late recurrence were often referred back to Yale Dermatologic Surgery for
evaluation. In this way, a large proportion of recurrences are likely to be detected in our
study. Survival groups here refer to the number of PDT treatments that patients received
within 1 year of previous treatment, before any recurrence or other treatment for
persistent disease occurred, and with follow-up data.
Treated lesion fields had a mean disease-free survival time of 13.379 months
(standard deviation of 2.0 months, C.I. [9.477, 17.280], 41 observations) if they only
received 1 consecutive PDT treatment, mean disease-free survival time of 13.590 months
(standard deviation of 2.3 months, C.I. [9.072, 18.107], 23 observations) if they received
2 PDT treatments meeting above criteria, and mean disease-free survival time of 0.933
months (insufficient data points to calculate standard deviation or C.I., 5 observations)
for >2 consecutive PDT treatments. Once again, months here refer to 30-day intervals
and not calendar months. The log-rank test revealed a statistically insignificant
discrepancy between the survival curves for the 1 PDT treatment group and the 2 PDT
treatments group, with a p-value of 0.801. One lesion that received 1 consecutive PDT
treatment did not have data on initial treatment response but did have usable data for the
survival function. (Figure 4).
Following 1 consecutive treatment, there were 12 failures total including 4
documented recurrences with a recurrence rate of 12% (4/33), and 29 censored entries;
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for 2 consecutive treatments, there were 10 failures total including 6 documented
recurrences with a recurrence rate of 32% (6/19), and 13 censored entries. None of the
lesions receiving >2 consecutive PDT treatments were documented to have a recurrence,
and apart from 2 lesions in this group with follow-up length of 33.6 months, the rest all
had follow-up lengths of 1.4 months or less.
Survival distribu-on func-on
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0

5

10

15

20

25

30

35

Disease-Free Interval
1

2

>2

Figure 4. Kaplan-Meier survival functions for 1, 2, and >2 consecutive PDT treatments
with follow-up data. Blue represents the group that received 1 treatment, green represents
2 PDT treatments, and red represents >2 consecutive PDT treatments. Only 5 lesions
were included in the last group.
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Mutation Burden Analysis
Since PDT treats the field surrounding a cancerous lesion as well as the lesion
itself, it may have a clinical role in treating field cancerization and preventing further
development of malignant cells. However, in the absence of visibly abnormal lesions,
clinical observation of field cancerization may not be possible. In order to better quantify
the risk posed by field cancerization in patients’ skin, a method using sequencing and
mutation burden analysis could prove useful.
A necessary step for mutation burden analysis would be collection of relevant
DNA samples for testing. Punch biopsy is a method that is often used by dermatologists
to collect skin samples and DNA can be extracted from these skin samples. DNA yield
depends upon number and size of biopsies and DNA purification method. 1mm diameter
punch biopsies fail to consistently yield sufficient DNA (≧1µg) for our study. Phenolchloroform extraction led to higher DNA yields than the QIAamp® kit. Individual 2mm
punch biopsies purified with phenol-chloroform extraction provided high DNA yields
while minimizing required biopsy material. As expected, DNA yields correlated
positively with punch biopsy size and the number of punch biopsies used in a single
sample. However, even two 2mm punch biopsies when purified with the QIAamp® kit,
with an average yield of 2.2µg and SD of 0.29 for 2 samples, yielded less DNA than one
2mm punch biopsy when using phenol-chloroform, with an average yield of 3.6µg and
SD of 2.3 for 7 samples. Three 2mm punch biopsies when purified with phenolchloroform had the highest average DNA yield of 6.5µg for 2 samples, with SD of 2.2.
(Figure 5).
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In order to sequence DNA samples for the mutation burden analysis, amplicons
including target sequences must first be generated. Initially, long-range PCR was
attempted but this proved unsuccessful. PCR results of more than 20 samples shows that
PCR amplification can occur fairly reliably up to slightly over 1.5kb in amplicon size
based on visual confirmation of gel electrophoresis, but PCR amplification of amplicon
sizes larger than that are not consistently successful. With some variation between
samples, PCR amplification of amplicon lengths around 1.5kb or less could sometimes be
achieved with 30 cycles or fewer, but amplification at higher amplicon lengths did not
yield visible bands at the right size even with 35 cycles or more. (Figure 6).
Subsequently, we attempted a different strategy using an extension-ligation
system marketed by Illumina®. Using Illumina, Inc.’s Design Studio ® software, primers
targeting the 5’ UTR and CDS of TP53, Hras, Nras, Kras, CDKN2a, Notch1, Notch2,
Notch3, Fat1, Fgfr3, Knstrn, Braf, and VHL (control gene), along with 10bp of intron
padding around these sequences, was generated. Extra padding was also designed around
important regions, such as regions with documented mutations in literature. These
primers should promote the amplification of 250bp amplicons and cover both DNA
strands of each target region utilizing dual-pool design. The cumulative target size was
59,547bp with 2 x 394 distinct amplicons. The design ultimately included 3 gaps totaling
a length of 276bp.
The first sequencing run generated with 20 skin samples from 8 skin cancer
patients yielded a total sequence of 1.54e11 bp with a quality score of 72.26%. Total
high-quality sequence generated was 1.11e11 bp in length, and the average sequence per
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sample was 5.57e9 bp. Dividing this last number by the total sequencing target size
(59,547 bp)leads to an average of 93,500-fold coverage per sample.
The bioinformatic analysis of sequencing results is ongoing.
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Figure 5. Comparison of DNA yield against punch biopsy number, diameter and
purification method.
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Figure 6. PCR results from purified genomic DNA extracted from human skin samples,
as an indicator of DNA quality. PCR amplification occurs fairly reliably up to 1.5kb
amplicon size, but did not work at >3kb amplicon sizes. A. Results of 30 and 26 cycles of
PCR, Hras primer set with expected amplicon size of 415bp, and 5ng template DNA
(except for 3.92ng for 4B and 1.5ng for 5A). B. PCR results with 35 cycles, TP53 primer
set with expected band sizes of 3567bp (A), 3727bp (B), 2912bp (C), and 5ng template
DNA. C. PCR results with 30 cycles, TP53 primer set with expected band size 1536bp,
and 25ng, 5ng, and 1ng of template DNA.
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DISCUSSION
While the complete response rate of 55% after 1 cycle of PDT may seem a bit
low, 83% (52/63) of lesions had a documented complete response with 1-2 cycles of
PDT. Following an incomplete initial response to PDT, only 65% (13/20) of lesions will
exhibit a complete response to a second round of PDT, suggesting diminishing marginal
returns with additional sessions of PDT. In contrast, 83% (19/23) of all patients with 2
consecutive PDT treatments had a complete response. This discrepancy is likely due to
patients not being randomly assigned to receive 1 or 2 cycles of PDT, but rather many
patients who received 2 cycles of PDT did so because their lesion did not completely
resolve after receiving 1 cycle of PDT. Furthermore, the difference in complete response
rates after 1 session of PDT versus 2 sessions of PDT was not statistically significant, and
the response rates themselves were not different. Therefore, initially starting a protocol
involving 2 PDT treatments may not be beneficial compared to initially starting a
protocol involving 1 PDT treatment, and given contemporary concerns over healthcare
costs as well as patient convenience, it may be worthwhile to initiate PDT with only 1
planned treatment and then decide whether to continue with more PDT sessions based on
the follow-up assessment.
Most of the literature published on PDT treatment for SCCIS involves multiples
PDT treatments, with reported complete response rates ranging from 75% to 100%. The
most relevant comparison may be our 83% complete response rate following 1-2 sessions
of PDT, which is within the range described by the literature. Complete response rate
after initial treatment does not appear to be an appropriate comparison since most other
studies did not limit themselves to 1 session of PDT if there was a clinical indication for
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more. Complete response rate after 1-2 sessions of PDT appears comparable to
imiquimod’s reported 75-93%[43, 44] and 5-FU’s 67-92% [43, 45]. Mohs surgery
certainly exceeds PDT’s complete response rate, since the surgery is designed to continue
until reaching 100% complete response rate, so if PDT is chosen instead of surgery there
is typically some reason other than response rate and considering this study did not find a
different response rate, it should not impact that decision.
Clinically, it is unlikely that patients would receive more than 2 cycles of PDT for
a persistent lesion unless there was some contraindication for definitive treatment such as
surgery, so evaluation of the efficacy of >2 cycles of PDT is challenging. Usually the
cycles would be spaced very far apart since they were not offered as part of the same
treatment sequence, but rather for a recurrence later in time or for another lesion in a
similar region. In our case, we had insufficient data on lesions receiving >2 cycles of
PDT to draw substantial conclusions.
This study was fairly unique in the sense that patients were treated with blue light
rather than red light, which has a shorter wavelength and in theory should more
efficiently generate ROS and free radicals. The downside is that blue light is less able to
penetrate deeply into tissue than red light, but the hope is that the superficial nature of
SCCIS would lessen the potential negative impact.
The logistic regression models for response after first PDT treatment and PDT
side-effects had relatively high pseudo R2 values and low p-values, suggesting that the
models fit the data fairly well and are likely significant. In contrast to linear regression
models, where R2 (without the “pseudo” in front) more directly indicates the amount of
variation in results that the model can account for with factor variables, logistic models
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do not obey the same assumptions regarding homogeneity of standard error values at
different points in the model, and thus the interpretation of the pseudo R2 and the
appropriate method of calculating pseudo R2 can be controversial. Furthermore, while R2
is easier to interpret because its range is constrained between [0,1], under certain
circumstances the lower bound of pseudo R2 is above 0 and the upper bound is below 1.
Another complication of regression models is that data points missing any of the
variables are completely excluded from the calculation of the model. While this may be
more justifiable than the alternative method of systematically replacing missing data with
certain values, it does mean that collecting more variables may lead to greater loss of data
and precision, since the more variables are collected, the greater the likelihood that any
data point would be missing some factor variable data.
In terms of precision and statistical significance, our study involved a fairly small
sample size, especially in comparison to the number of variables that we were analyzing,
which made statistical significance less likely. Given that we had some factor variables
that were not statistically significant but close to statistical significance, further study
with larger sample sizes may lead to more statistically significant findings.
Regression models also run the risk that strong correlation to an independent
variable may actually indicate a relationship with a confounding factor left out of the
model.
For complete response after initial PDT treatment, increasing age and large size
were found to significantly correlate against complete response. Normally, if a treatment
is less likely to be successful, the recommendation may be to preferentially pursue other
types of treatment, but unfortunately increasing age and large size can also be
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contraindications to surgery, which is often the reason why PDT is pursued in the first
place. Since PDT has fewer side-effects than surgery, especially in this population, it may
be worth pursuing as initial treatment anyway.
Side-effects of pain and erythema were significantly correlated with
photosensitizer incubation time and with the presence of each other. While regression
models indicate correlation and not causation, incubation times were chosen by the
provider and possibly influenced by scheduling circumstances of the patient, but are
otherwise unlikely to have been influenced by anything that could have served as a
confounding variable for pain and erythema, and since the side-effects of pain and
erythema strictly occur temporally after incubation time has already been fixed, it is
likely that the relationship is one of causality and not merely correlation. Since incubation
occurs because ALA needs time for absorption and metabolism into the photosensitizer
PPIX, it makes theoretical sense for the side-effects of PDT to be caused by this step in
the treatment procedure. The significant correlation between the presence of one sideeffect and the other is not counterintuitive, since they are both occurring as a result of the
same treatment. Although at first glance it might seem surprising that the odds ratios are
not equal between that of pain as a factor variable and erythema as the dependent variable
and vice versa, there are many cases of highly correlated conditions that would not have
the same odds ratio as that of the converse case, such as with fair skin and skin cancer
diagnosis or with pregnancy status and female sex.
Since the main goal of PDT treatment is clearance of SCCIS and prevention of
recurrence, I do not think that incubation time should be adjusted with the purpose of
avoiding or minimizing side-effects.
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In terms of the disease-free survival analysis, the main difficulty is that the true
recurrence rate is probably too low in relation to our follow-up lengths for us to reliably
model the survival function. As a carcinoma in-situ, SCCIS is not as aggressive as
invasive SCC, it may be less likely to recur and its recurrence may take longer. Previous
studies that looked specifically at long-term recurrence rates had average follow-up
lengths of 43.5-60 months, with recurrence rates of 11.6%, 54%, and 57% [105, 106,
108], which shows fairly large variation. Our recurrence rates of 12% (4/33) for 1 PDT
treatment and 32% (6/19) for 2 PDT treatments are on the lower end of the reported
range, but our follow-up time of 15 days to 37 months is also much shorter.
Even so, surgery has lower reported recurrence rates of 4.6%-8.3%.[39-42] From
the perspective of preventing recurrences, surgery is clearly the superior treatment
method, which means that if PDT is being utilized instead of surgery, it is for other
reasons that outweigh the consideration of recurrence rate. This study highlights the fact
that PDT treatment of SCCIS may have a recurrence rate as high as 1 in 3, and this must
be considered when deciding between PDT and other forms of treatment such as surgery.
Other than lesion size and patient age, this study does not identify specific factors
correlated with PDT response, and the clinical considerations that ultimately lead to
choosing PDT over surgery should remain unchanged.
Additionally, one challenge of this being a retrospective study is the lack of
systematic follow up. This means that in practice, patients may only visit the clinic for
procedures and short-term follow-up, and then resume follow-ups with their primary
dermatologist, with referrals back to the dermatological surgery clinic in case of
recurrence or a new lesion that requires specialty procedures. Therefore, the observed
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disease-free survival intervals are likely shorter than the true disease-free survival
intervals, since patients who remain disease-free may never return. Paradoxically, it is
possible that some of the patients with the longest disease-free survival intervals may
have the shortest documented disease-free survival lengths based on follow-up visits.
The survival curves that I obtained for 1 consecutive PDT treatment versus 2
consecutive PDT treatments were not statistically significant, had very similar mean
disease-free survival times, and even appeared to overlap visually. Therefore, additional
PDT treatments for the purpose of preventing future disease, or PDT treatments “just in
case” after a complete response to initial treatment, are not clinically indicated and may
lead to unnecessary discomfort and usage of healthcare resources.
To summarize, since 1 consecutive cycle of PDT and 2 consecutive cycles of PDT
have similar complete response rates and disease-free survival functions, an additional
cycle of PDT is not indicated unless complete response was not achieved following initial
PDT treatment. 65% (13/20) of lesions that did not have a complete response to initial
treatment displayed a complete response to a second round of PDT, suggesting there is
some utility to continuing PDT after a failed treatment. However, it is between the patient
and the doctor at that point to decide whether to continue PDT or pursue other treatment
modalities. Since this study does not significantly change current knowledge of PDT’s
response and recurrence rates, decisions between PDT and surgery should depend on the
existing decision-making variables of patient preference, patient-specific factors that
make him a poor surgical candidate, and lesion-specific factors that contraindicate
surgery such as large size and sensitive location. However, as this study has shown, some
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of the factors such as increasing age and large lesion size that make surgery a less
desirable choice may also decrease the effectiveness of PDT.
The project analyzing mutation burden in normal sun-damaged skin is still in
process, and we have yet to perform the sequencing analysis. In the future, the results of
this project could potentially be used to identify an individual patients’ subsequent risk of
developing skin cancer based on mutation burden, with prospective determination of
mutation burden with clinical follow-up to assess cancer development. Clinical
application of this information may also allow more appropriate screening and preventive
treatment in high-risk patients. Punch biopsy, the method used to obtain DNA, is already
commonly used in dermatology clinics and is therefore readily available. Mutation
burden analysis in individual patients may also facilitate the monitoring of clinical
response to photodynamic therapy (PDT) and other dermatological treatments.
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